



US007230015B2

(12) **United States Patent**  
**Smith et al.**

(10) **Patent No.:** **US 7,230,015 B2**  
(45) **Date of Patent:** **Jun. 12, 2007**

(54) **METHOD OF TREATING OF  
DEMYELINATING DISEASES OR  
CONDITIONS**

(75) Inventors: **Craig P Smith**, Hillsborough, NJ (US);  
**Michel P Rathbone**, Hamilton, CA  
(US); **Margaret Petty**, Bridgewater, NJ  
(US); **David Rampe**, Bernardsville, NJ  
(US)

(73) Assignee: **Aventis Pharmaceuticals Inc.**,  
Bridgewater, NJ (US)

(\*) Notice: Subject to any disclaimer, the term of this  
patent is extended or adjusted under 35  
U.S.C. 154(b) by 30 days.

(21) Appl. No.: **11/079,327**

(22) Filed: **Mar. 14, 2005**

(65) **Prior Publication Data**

US 2005/0159456 A1 Jul. 21, 2005

**Related U.S. Application Data**

(60) Continuation of application No. 10/770,655, filed on  
Feb. 3, 2004, now abandoned, which is a division of  
application No. 10/076,191, filed on Feb. 14, 2002,  
now Pat. No. 6,967,210.

(60) Provisional application No. 60/268,846, filed on Feb.  
15, 2001.

(30) **Foreign Application Priority Data**

Aug. 9, 2001 (GB) ..... 0119435.6

(51) **Int. Cl.**  
**A61K 31/44** (2006.01)

(52) **U.S. Cl.** ..... **514/339**; 514/323; 514/336;  
514/337; 514/903

(58) **Field of Classification Search** ..... None  
See application file for complete search history.

(56) **References Cited**

**U.S. PATENT DOCUMENTS**

4,970,218 A 11/1990 Efland et al.  
5,519,131 A 5/1996 Efland et al.

**FOREIGN PATENT DOCUMENTS**

DE 43 25 491 2/1995

EP	0287982	12/1994
EP	0415103	2/1995
EP	0731108	9/1996
EP	0683165	8/2000
WO	WO 96/14066	5/1996
WO	WO 01/04091	1/2001

**OTHER PUBLICATIONS**

Bever, C.T., et. al., The Current Status of Studies of Aminopyridines in Patients with Multiple Sclerosis, *Annals of Neurology*, Boston, MA, vol. 36, 1994, pp. S118-S121.

Tang, L., et. al., 4-Aminopyridine Derivatives: A Family of Novel Modulators of Voltage-Dependent Sodium Channels, *Drug Development Research*, vol. 44, No. 1, May 1998, pp. 8-13.

Tang, L., et. al., Effects of besipirdine at the voltage-dependent sodium channel, *British Journal of Pharmacology*, vol. 116, No. 5, 1995, pp. 2468-2472.

Abou-Gharbia, M., et. al., IV Congress of the ECNP, Aggression and anxiety are the first components to respond to antidepressant therapy, *Drug News and Perspectives*, vol. 4, No. 10, Dec. 1, 1991, pp. 647-650.

Villoslada, P., et. al., Human Nerve Growth Factor Protects Common Marmosets against Autoimmune Encephalomyelitis by Switching the Balance of T Helper Cell Type 1 and 2 Cytokines within the Central Nervous System, *Journ. of Experimental Medicine*, vol. 191, No. 10, May 15, 2000, pp. 1799-1806.

Eglen, R.M., et. al., Muscarinic receptor ligands and their therapeutic potential, *Current Opinion in Chemical Biology*, vol. 3, No. 4, Aug. 1999, pp. 426-432.

Stedman's, No title—Stedman's Medical Dictionary, Stedman's Medical Dictionary, 25th Edition, Illustrated, 1994, pp. 391.

Mysiw, M.J., et. al., Medications To Enhance Cognitive Functioning, *Physical Medicine and Rehabilitation Clinics of North America*, 1997, pp. 781-800.

*Primary Examiner*—Dwayne Jones

(74) *Attorney, Agent, or Firm*—Barbara E. Kurys

(57) **ABSTRACT**

N-(Pyridinyl)-1H-indol-1-amines of formula I provide a unique combination of blocking properties for both the potassium and sodium channels. These compounds are useful for the treatment of Demyelinating Diseases and Conditions such as Multiple Sclerosis, Spinal Cord Injury, Traumatic Brain Injury and Stroke. The compounds are also useful for Stroke Rehabilitation, the treatment of Bladder Irritation and Dysfunction, and the treatment of Neuropathic Pain and Chemokine-Induced Pain.

**2 Claims, 11 Drawing Sheets**